Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half ...
Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...
Count Me In, a patient-partnered research initiative led by Dana-Farber Cancer Institute and the Broad Institute of MIT and ...
MSD has opened a $1bn facility in Durham located in the US state of North Carolina, to increase vaccine manufacturing ...
23h
Count Me In, a patient-partnered research initiative led by the Broad Institute of MIT and Harvard and Dana-Farber Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback